ASH 2023 | Addressing the high rate of disease relapse following alloSCT in patients with AML
Despite significant reductions in transplant-related mortality following allogeneic stem cell transplantation (alloSCT) over the past two decades as a result of improved infection prevention and graft versus host disease (GvHD) prophylaxis, the persistently high rate of disease relapse post-transplant has been insufficiently addressed. Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, FMedSci, University of Birmingham, discusses measures that should be taken to decrease the number of patients relapsing following alloSCT for acute myeloid leukemia (AML). These include improving conditioning regimens, minimizing pre-transplant measurable residual disease (MRD) levels, and maximizing the graft vs leukemia effect post-transplant. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: BMS, Abbvie
Research Funding: BMS
